Primary coenzyme Q10 Deficiency-6 (COQ10D6): Two siblings with variable expressivity of the renal phenotype.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 01 06 2018
revised: 22 11 2018
accepted: 19 01 2019
pubmed: 27 1 2019
medline: 2 10 2020
entrez: 26 1 2019
Statut: ppublish

Résumé

Primary coenzyme Q10 deficiency-6 (COQ10D6) is a rare autosomal recessive disorder caused by COQ6 mutations. The main clinical manifestations are infantile progressive nephrotic syndrome (NS) leading to end-stage renal disease and sensorineural deafness. A 7-year-old girl was diagnosed with steroid-resistant NS (SRNS) and an audiological work-up revealed bilateral sensorineural deafness. A renal biopsy demonstrated focal segmental glomerulosclerosis. Despite immunosuppressive therapy, her serum levels of creatinine increased and haemodialysis was indicated within 1 year after the diagnosis. Living-donor kidney transplantation was performed in the eighth month of haemodialysis. A diagnostic custom-designed panel-gene test including 30 genes for NS revealed homozygous c.1058C > A [rs397514479] in exon nine of COQ6. Her older brother, who had sensorineural hearing loss with no renal or neurological involvement, had the same mutation in homozygous form. COQ6 mutations should be considered not only in patients with SRNS with sensorineural hearing loss but also in patients with isolated sensorineural hearing loss with a family history of NS. The reported p.His174 variant of COQ8B was suggested to be a risk factor for secondary CoQ deficiency, while p.Arg174 appeared to improve the condition in a yeast model. Family segregation and the co-occurrence of biallelic p.Arg174 of COQ8B in a brother with hearing loss implied that the interaction of the altered COQ8B with the mutant COQ6 alleviated the symptoms in this family. CoQ10 replacement therapy should be initiated for these patients, as primary CoQ10 deficiency is considered the only known treatable mitochondrial disease.

Identifiants

pubmed: 30682496
pii: S1769-7212(18)30328-8
doi: 10.1016/j.ejmg.2019.01.011
pii:
doi:

Substances chimiques

ubiquinone 6 1065-31-2
Ubiquinone 1339-63-5
coenzyme Q10 EJ27X76M46

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103621

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Zeynep Yuruk Yildirim (Z)

Istanbul University, Istanbul Faculty of Medicine, Pediatric Nephrology Department, Istanbul, Turkey. Electronic address: znyuruk@gmail.com.

Guven Toksoy (G)

Istanbul University, Istanbul Faculty of Medicine, Department of Medical Genetics, Istanbul, Turkey.

Oya Uyguner (O)

Istanbul University, Istanbul Faculty of Medicine, Department of Medical Genetics, Istanbul, Turkey.

Ahmet Nayir (A)

Istanbul University, Istanbul Faculty of Medicine, Pediatric Nephrology Department, Istanbul, Turkey.

Sevgi Yavuz (S)

Kanuni Sultan Suleyman Research and Training Hospital, Pediatric Nephrology Department, Istanbul, Turkey.

Umut Altunoglu (U)

Istanbul University, Istanbul Faculty of Medicine, Department of Medical Genetics, Istanbul, Turkey.

Ozde Nisa Turkkan (ON)

Istanbul University, Istanbul Faculty of Medicine, Pediatric Nephrology Department, Istanbul, Turkey.

Burcu Sevinc (B)

Istanbul University, Istanbul Faculty of Medicine, Department of Medical Genetics, Istanbul, Turkey.

Gulden Gokcay (G)

Istanbul University, Istanbul Faculty of Medicine, Pediatric Nutrition and Metabolism Department, Istanbul, Turkey.

Dilek Kurkcu Gunes (D)

Istanbul University, Istanbul Faculty of Medicine, Pediatric Nutrition and Metabolism Department, Istanbul, Turkey.

Aysel Kiyak (A)

Kanuni Sultan Suleyman Research and Training Hospital, Pediatric Nephrology Department, Istanbul, Turkey.

Alev Yilmaz (A)

Istanbul University, Istanbul Faculty of Medicine, Pediatric Nephrology Department, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH